Clinical Updates on Rheumatoid Arthritis: 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 497

Special Issue Editor


E-Mail Website
Guest Editor
Rheumatology Department Usl Tuscany Center, Santa Maria Nuova Hospital, Santa Maria Nuova Square 1, 50122 Florence, Italy
Interests: clinical rheumatology; rheumatic diseases; chronic inflammation; rheumatoid arthritis; spondyloarthritis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is my pleasure to invite you to contribute to the Special Issue entitled “Clinical Updates on Rheumatoid Arthritis: 2nd Edition”. This is one new volume we published six papers in the first volume. For more details, please visit:
https://www.mdpi.com/journal/jcm/special_issues/N185GRN1UY.

Rheumatoid arthritis (RA) is a chronic inflammatory systemic disease induced by a complex interaction between shared epitope genes, microbiota, innate immune mechanisms, autoimmunity, and environmental factors, including tobacco, that primarily involves synovial joints, but that might also evolve into interstitial lung and cardiovascular diseases, and rarely, vasculitis. In recent years, research progress has highlighted that there may be different RA patterns reflected by biopsy-based biomarkers that are gender-oriented. Furthermore, advances in imaging technology, particularly MRI and ultrasonography, have led to an earlier diagnosis of active and erosive pre-radiographic disease. The discovery of new biomarkers has improved our knowledge regarding the predictivity of the evolution of undifferentiated arthritis in definitive and erosive disorders. Furthermore, the COVID-19 pandemic had severe consequences on the daily practice of patients and complicated the course of the disease, but the use of telemedicine and artificial intelligence has improved the traditional follow-up of RA patients. Recent guidelines for the treatment of RA include the use of JAK inhibitors along with the best known traditional biological treatments, but the increasing number of therapies might sometimes be confounding. Hopefully, the possibility to match laboratory, gender, imaging, and histological characteristics and systemic disease might lead to a more tailored choice of treatment in the near future.

Outstanding experts interested in this Special Issue are welcome to submit original manuscripts and reviews dealing with any of the abovementioned aspects of RA research.

Dr. Francesca Bandinelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rheumatoid arthritis
  • rheumatology
  • treatment
  • diagnosis
  • biomarkers
  • rheumatic disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

11 pages, 959 KiB  
Case Report
Experience of High Tibial Osteotomy for Patients with Rheumatoid Arthritis Treated with Recent Medication: A Case Series
by Yasuhiro Takahara, Hirotaka Nakashima, Keiichiro Nishida, Yoichiro Uchida, Hisayoshi Kato, Satoru Itani and Yuichi Iwasaki
J. Clin. Med. 2025, 14(10), 3332; https://doi.org/10.3390/jcm14103332 - 10 May 2025
Viewed by 240
Abstract
Background: High tibial osteotomy (HTO) was generally not indicated in patients with rheumatoid arthritis (RA) because synovial inflammation may exacerbate joint damage postoperatively. Recently, joint destruction in RA has dramatically changed with the introduction of methotrexate (MTX) and biological disease-modifying antirheumatic drugs [...] Read more.
Background: High tibial osteotomy (HTO) was generally not indicated in patients with rheumatoid arthritis (RA) because synovial inflammation may exacerbate joint damage postoperatively. Recently, joint destruction in RA has dramatically changed with the introduction of methotrexate (MTX) and biological disease-modifying antirheumatic drugs (bDMARDs). This study aimed to investigate the clinical outcomes of HTO for patients with RA treated with recent medication. Methods: In this study, patients with RA who underwent HTO between 2016 and 2020 were retrospectively reviewed. Patients whose follow-up period was <2 years and those whose onset of RA occurred after HTO were excluded. Clinical outcomes were investigated using the Japanese orthopedic Association (JOA) and visual analog scale (VAS) scores. Results: Seven patients (two males and five females, mean age 72.0 ± 6.2 years, mean body mass index 24.0 ± 2.9 kg/m2) were included in this study. The mean follow-up period was 62.1 ± 21.4 months. Open-wedge and hybrid closed-wedge HTO were performed in two and five cases, respectively. MTX was used for all cases. The bDMARDs were used in six cases (golimumab and tocilizumab in four and two cases, respectively). JOA scores significantly improved from 63.6 ± 10.7 preoperatively to 90.7 ± 5.3 postoperatively (p = 0.0167 Wilcoxon rank test). VAS scores significantly decreased from 48.6 ± 12.2 preoperatively to 11.4 ± 6.9 postoperatively (p = 0.017 Wilcoxon rank test). None of the patients underwent total knee arthroplasty. Conclusions: This study showed seven RA patients who underwent HTO treated with recent medication. The prognosis of RA, including joint destruction, has dramatically improved with induction of MTX and bDMARDs. HTO may be one of effective joint preservation surgeries even for patients with RA. To achieve the favorable outcomes, surgeons should pay attention to timing and indication of surgery. Full article
(This article belongs to the Special Issue Clinical Updates on Rheumatoid Arthritis: 2nd Edition)
Show Figures

Figure 1

Back to TopTop